ERBB2 and gastroesophageal junction adenocarcinoma: In the DESTINY-Gastric01 trial, T-DXd 6·4 mg/kg demonstrated significant clinical benefit in patients from Japan and the Republic of Korea with HER2+ locally advanced or metastatic gastric or GEJ adenocarcinoma that had progressed after at least two previous therapies, including trastuzumab.